Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

January 31, 2015

Conditions
StrokeIschemic StrokeStroke in Middle Cerebral Artery (MCA)
Interventions
BIOLOGICAL

ALD-401

3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.

PROCEDURE

Sham Procedure

Sham bone marrow harvest and sham product infusion procedures.

Trial Locations (9)

15213

University of Pittsburgh Medical Center Presbyterian Hospital, Pittsburgh

27710

Duke University Medical Center, Durham

33136

University of Miami Hospital, Miami

43214

Ohio Health Research Institute, Columbus

55407

Minneapolis Heart Institute, Minneapolis

77030

The University of Texas Medical School, Houston

78701

University Medical Center at Brackenridge, Austin

90027

Los Angeles Brain and Spine Institute, Los Angeles

98122

Swedish Medical Center, Cherry Hill Campus, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aldagen

INDUSTRY

NCT01273337 - Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects | Biotech Hunter | Biotech Hunter